Straits Times Index
3,321.30 -4.98 (-0.15%) Nikkei
39,667.07 +493.92 (+1.26%) Hang Seng
18,136.00 +63.10 (+0.35%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,544.32 +411.93 (+0.67%) CMC Crypto 200
1,278.91 -4.88 (-0.38%)
Telix Pharmaceuticals Limited (TLX.AX)
| Previous close | 18.86 |
| Open | 18.70 |
| Bid | 18.91 x 993000 |
| Ask | 18.92 x 862200 |
| Day's range | 18.65 - 19.02 |
| 52-week range | 8.20 - 19.06 |
| Volume | |
| Avg. volume | 1,172,856 |
| Market cap | 6.318B |
| Beta (5Y monthly) | 2.43 |
| PE ratio (TTM) | 945.50 |
| EPS (TTM) | 0.02 |
| Earnings date | 21 Aug 2024 - 26 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.89 |
GlobeNewswireTelix Announces Launch of Proposed Initial Public Offering in the United States
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix. The target size of the Offering is US$200 million in gross proceeds. In addition, Telix expects to grant the Underwriters (as defined below) a 30-day option to purchase up to an additional 15%
PR NewswireTelix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET[1] agent, TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC).
- PR Newswire
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces additional positive data from the ProstACT SELECT trial ("SELECT") of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC). SELECT is a radiogenomics study intended to evaluate lesion concordance between 68Ga (gallium)-based PSMA-PET[4] imaging and TLX591 dosimetry for the purpose of validating
